{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:31:36Z","timestamp":1788345096585,"version":"build-2803163510"},"reference-count":40,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":69,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7\u20136.4%) and total testosterone levels \u226412.1 nmol\/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>HbA1c decreased by 0.39 \u00b1 0.03% (P &amp;lt; 0.0001) in the T-group and increased by 0.63 \u00b1 0.1% (P &amp;lt; 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c &amp;lt;5.7%). In the untreated group, 40.2% progressed to T2D (HbA1c &amp;gt;6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males\u2019 Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P &amp;lt; 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P &amp;lt; 0.005).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc18-2388","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T21:55:16Z","timestamp":1552427716000},"page":"1104-1111","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":150,"title":["Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study"],"prefix":"10.2337","volume":"42","author":[{"given":"Aksam","family":"Yassin","sequence":"first","affiliation":[{"name":"Institute for Urology and Andrology, Norderstedt, Germany"},{"name":"Dresden International University, Dresden, Germany"},{"name":"Division of Urology\/Andrology, Department of Surgery, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Haider","sequence":"additional","affiliation":[{"name":"Private Urology Practice, Bremerhaven, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim S.","family":"Haider","sequence":"additional","affiliation":[{"name":"Private Urology Practice, Bremerhaven, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Caliber","sequence":"additional","affiliation":[{"name":"American Medical Writers Association, Fort Lauderdale, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe","family":"Doros","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-6635","authenticated-orcid":false,"given":"Farid","family":"Saad","sequence":"additional","affiliation":[{"name":"Medical Affairs Andrology, Bayer AG, Berlin, Germany"},{"name":"Gulf Medical University School of Medicine, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-0860","authenticated-orcid":false,"given":"W. Timothy","family":"Garvey","sequence":"additional","affiliation":[{"name":"Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"2022031300000836700_B1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00592-018-1163-6","article-title":"The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men","volume":"55","author":"Gyawali","year":"2018","journal-title":"Acta Diabetol"},{"key":"2022031300000836700_B2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12020-014-0436-2","article-title":"Prediabetes and associated disorders","volume":"48","author":"Buysschaert","year":"2015","journal-title":"Endocrine"},{"key":"2022031300000836700_B3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/dc08-2216","article-title":"Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: Multi-Ethnic Study of Atherosclerosis","volume":"32","author":"Colangelo","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B4","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1210\/jc.2004-0804","article-title":"Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes","volume":"89","author":"Dhindsa","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300000836700_B5","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/dc09-1649","article-title":"Testosterone concentrations in diabetic and nondiabetic obese men","volume":"33","author":"Dhindsa","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B6","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc18-Srev01","article-title":"Summary of revisions: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/diacare.23.7.912","article-title":"Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women","volume":"23","author":"Goodman-Gruen","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2213-8587(15)00362-9","article-title":"Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study","volume":"4","author":"Ligthart","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300000836700_B9","first-page":"141","article-title":"The prevalence of prediabetes in population of Polish men with late-onset hypogonadism","volume-title":"Aging Male","author":"Rabijewski","year":"2014"},{"key":"2022031300000836700_B10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13679-015-0155-x","article-title":"Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action","volume":"4","author":"Grams","year":"2015","journal-title":"Curr Obes Rep"},{"key":"2022031300000836700_B11","first-page":"1","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity","volume-title":"Endocr Pract","author":"Garvey","year":"2016"},{"key":"2022031300000836700_B12","unstructured":"National Diabetes Education Program (NDEP). Guiding Principles for the Care of People With or at Risk for Diabetes [Internet], 2018. Available from https:\/\/www.niddk.nih.gov\/health-information\/communication-programs\/ndep\/health-professionals\/guiding-principles-care-people-risk-diabetes. Accessed 29 August 2018"},{"key":"2022031300000836700_B13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ijo.2015.139","article-title":"Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies","volume":"40","author":"Saad","year":"2016","journal-title":"Int J Obes"},{"key":"2022031300000836700_B14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1074248417691136","article-title":"Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups","volume":"22","author":"Traish","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022031300000836700_B15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in\u00a0Hungary","volume":"241","author":"Mark","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022031300000836700_B16","doi-asserted-by":"crossref","first-page":"e8461","DOI":"10.1097\/MD.0000000000008461","article-title":"Change in nonhigh-density lipoprotein cholesterol levels in adults with prediabetes","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2022031300000836700_B17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease","volume":"96","author":"McLaughlin","year":"2005","journal-title":"Am J Cardiol"},{"key":"2022031300000836700_B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/eci.12583","article-title":"The TyG index may predict the development of cardiovascular events","volume":"46","author":"S\u00e1nchez-\u00cd\u00f1igo","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2022031300000836700_B19","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1210\/jc.2010-0288","article-title":"The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp","volume":"95","author":"Guerrero-Romero","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300000836700_B20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study","volume":"22","author":"Look AHEAD Research Group","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"2022031300000836700_B21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ijo.2013.180","article-title":"The challenge of a 2-year follow-up after intervention for weight loss in primary care","volume":"38","author":"Holzapfel","year":"2014","journal-title":"Int J Obes"},{"key":"2022031300000836700_B22","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"2022031300000836700_B23","first-page":"A305","article-title":"Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years","volume":"66","author":"Saad","year":"2017","journal-title":"Diabetes"},{"key":"2022031300000836700_B24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2022031300000836700_B25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bju.14536","article-title":"Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors","volume":"123","author":"Hackett","year":"2019","journal-title":"BJU Int"},{"key":"2022031300000836700_B26","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1530\/EJE-15-0262","article-title":"Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study","volume":"174","author":"Corona","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2022031300000836700_B27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/gerona\/glr022","article-title":"Glucose and insulin measurements from the oral glucose tolerance test and relationship to muscle mass","volume":"67","author":"Kalyani","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2022031300000836700_B28","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1210\/jc.2011-0435","article-title":"Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey","volume":"96","author":"Srikanthan","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300000836700_B29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/eje.1.02166","article-title":"Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes","volume":"154","author":"Kapoor","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2022031300000836700_B30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study)","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/dc15-1518","article-title":"Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes","volume":"39","author":"Dhindsa","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2310\/JIM.0000000000000044","article-title":"Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men","volume":"62","author":"Vega","year":"2014","journal-title":"J Investig Med"},{"key":"2022031300000836700_B33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2022031300000836700_B34","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/diacare.28.8.1916","article-title":"Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes","volume":"28","author":"Liu","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031300000836700_B35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022031300000836700_B36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National Lipid Association Annual Summary of Clinical Lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2022031300000836700_B37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s00125-017-4275-6","article-title":"Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study","volume":"60","author":"Hulman","year":"2017","journal-title":"Diabetologia"},{"key":"2022031300000836700_B38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/dom.13241","article-title":"Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: experience from the AMORIS study","volume":"20","author":"Malmstr\u00f6m","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031300000836700_B39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S2213-8587(17)30097-9","article-title":"The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study","volume":"5","author":"Bommer","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300000836700_B40","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13601","article-title":"Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): design and implementation of a double-blind randomized controlled trial","author":"Wittert","year":"2018","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc18-2388","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/1104\/552956\/dc182388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/1104\/552956\/dc182388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:59:31Z","timestamp":1647143971000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/6\/1104\/36012\/Testosterone-Therapy-in-Men-With-Hypogonadism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,12]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-2388","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]}}}